News
FDA blocks early nod for Lilly's Alzheimer's drug donanemab
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track
